Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Lixte Biotechnology Holdings stock (Lixte Biotechnology Holdings)

Buy Lixte Biotechnology Holdings stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Lixte Biotechnology Holdings is a biotechnology business based in the US. Lixte Biotechnology Holdings shares (LIXT) are listed on the NASDAQ and all prices are listed in US Dollars. Lixte Biotechnology Holdings employs 3 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Lixte Biotechnology stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Lixte Biotechnology Holdings stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – LIXT. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Lixte Biotechnology Holdings stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Not rated yet
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Lixte Biotechnology Holdings stock price (NASDAQ: LIXT)

Use our graph to track the performance of LIXT stocks over time.

Lixte Biotechnology Holdings shares at a glance

Information last updated 2024-07-14.
Latest market close$2.41
52-week range$1.58 - $9.50
50-day moving average $2.48
200-day moving average $2.53
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.27

Is it a good time to buy Lixte Biotechnology Holdings stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lixte Biotechnology Holdings price performance over time

Historical closes compared with the close of $2.41 from 2024-07-15

1 week (2024-07-09) 7.11%
1 month (2024-06-14) -1.63%
3 months (2024-04-16) -31.14%
6 months (2024-01-16) 33.89%
1 year (2023-07-14) -55.62%
2 years (2022-07-15) 193.90%
3 years (2021-07-16) 2.89
5 years (2019-07-16) 4.56

Lixte Biotechnology Holdings financials

Gross profit TTM $0
Return on assets TTM -73.97%
Return on equity TTM -130.17%
Profit margin 0%
Book value $-0.17
Market Capitalization $5.4 million

TTM: trailing 12 months

Lixte Biotechnology Holdings share dividends

We're not expecting Lixte Biotechnology Holdings to pay a dividend over the next 12 months.

You may also wish to consider:

Have Lixte Biotechnology Holdings's shares ever split?

Lixte Biotechnology Holdings's shares were split on a 1:10 basis on 4 June 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lixte Biotechnology Holdings shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Lixte Biotechnology Holdings shares which in turn could have impacted Lixte Biotechnology Holdings's share price.

Lixte Biotechnology Holdings share price volatility

Over the last 12 months, Lixte Biotechnology Holdings's shares have ranged in value from as little as $1.58 up to $9.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lixte Biotechnology Holdings's is -0.216. This would suggest that Lixte Biotechnology Holdings's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lixte Biotechnology Holdings has bucked the trend.

To put Lixte Biotechnology Holdings's beta into context you can compare it against those of similar companies.

Lixte Biotechnology Holdings overview

Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases. The company primarily focuses on inhibitors of protein phosphatase 2A that are used in combination with cytotoxic agents and/or x-ray, immune checkpoint blockers and other cancer therapies. It develops LB-100 that has completed phase I clinical trial for advanced soft tissue carcinoma and small cell lung cancer, as well as is in Phase II clinical trial for ovarian clear cell cancer. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc. ; license agreements with National Institute of Health and Moffitt Cancer Center; and collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group and Oncode Institute, as well as Roche and the Netherlands Cancer Institute for conducting new clinical trial in immune therapy unresponsive metastatic colon cancer.

Frequently asked questions

What percentage of Lixte Biotechnology Holdings is owned by insiders or institutions?
Currently 20.482% of Lixte Biotechnology Holdings shares are held by insiders and 6.148% by institutions.
How many people work for Lixte Biotechnology Holdings?
Latest data suggests 3 work at Lixte Biotechnology Holdings.
When does the fiscal year end for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings's fiscal year ends in December.
Where is Lixte Biotechnology Holdings based?
Lixte Biotechnology Holdings's address is: 680 East Colorado Boulevard, Pasadena, CA, United States, 91101
What is Lixte Biotechnology Holdings's ISIN number?
Lixte Biotechnology Holdings's international securities identification number is: US5393192027

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site